Drugs / Ro 24-7429
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00000760 | — | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00002314 | — | HIV infectious disease, Kaposi's sarcoma | Hoffmann-La Roche | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ro 24-7429 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00002314 ↗ |
| Action | Inhibit | “tat (transactivator of transcription of HIV) antagonist” NCT00000760 ↗ |
| Modality | Small molecule | — CHEMBL2360841 ↗ |
| Route | Oral | “receive oral Ro 24-7429” NCT00000760 ↗ |